Vivo Capital, a global investment firm, led a $200m investment in Avistone, a clinical-stage biotechnology company. Addition investors include Bain Capital and Primavera Capital. “Avistone is a science-driven, innovative biotechnology company committed to the discovery and clinical development of first-in-class and best-in-class drugs. We are thrilled for our company, team, and product pipeline to be recognized by such well-established global life sciences investors as Vivo Capital, Bain Capital, and Primavera Capital. We look forward to leveraging their resources and capabilities to realize our vision to become a global oncology leader that provides more effective treatment options and improves quality of life for patients around the world," Hepeng Shi, Avistone Chairman, CEO, and Founder.